Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP‐ALL After Tisagenlecleucel: A Case Series

Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP‐ALL After Tisagenlecleucel: A Case Series

ABSTRACT Background CD19‐directed chimeric antigen receptor T‐cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). However, around 50% of patients relapse after tisagenlecleu...

Full description

Saved in:
Bibliographic Details
Main Authors: Margo Aertgeerts, Marleen Renard, Anne Uyttebroeck, Nancy Boeckx, Heidi Segers
Format: Article
Language:English
Published: Wiley 2025-03-01
Series:Cancer Reports
Subjects:
anti‐CD19 CAR T‐cell therapy
inotuzumab ozogamicin
relapsed/refractory BCP‐ALL
Online Access:https://doi.org/10.1002/cnr2.70177
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items